Exact Mass: 767.3153

Exact Mass Matches: 767.3153

Found 21 metabolites which its exact mass value is equals to given mass value 767.3153, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Pentagastrin

(3S)-3-{[(2S)-1-hydroxy-2-{[(2S)-1-hydroxy-2-[(1-hydroxy-3-{[hydroxy(2-methylpropoxy)methylidene]amino}propylidene)amino]-3-(1H-indol-3-yl)propylidene]amino}-4-(methylsulphanyl)butylidene]amino}-3-{[(1S)-1-(C-hydroxycarbonimidoyl)-2-phenylethyl]-C-hydroxycarbonimidoyl}propanoic acid

C37H49N7O9S (767.3312)


Pentagastrin is only found in individuals that have used or taken this drug. It is a synthetic pentapeptide that has effects like gastrin when given parenterally. It stimulates the secretion of gastric acid, pepsin, and intrinsic factor, and has been used as a diagnostic aid. [PubChem]The exact mechanism by which pentagastrin stimulates gastric acid, pepsin, and intrinsic factor secretion is unknown; however, since pentagastrin is an analogue of natural gastrin, it is believed that it excites the oxyntic cells of the stomach to secrete to their maximum capacity. Pentagastrin stimulates pancreatic secretion, especially when administered in large intramuscular doses. Pentagastrin also increases gastrointestinal motility by a direct effect on the intestinal smooth muscle. However, it delays gastric emptying time probably by stimulation of terminal antral contractions, which enhance retropulsion. Pentagastrin (ICI-50123) is a potent, selective Cholecystokinin B (CCKB) receptor antagonists with IC50 values of 11 nM and 1100 nM for CCKB and CCKA, respectively. Pentagastrin enhances gastric mucosal defense mechanisms against acid and protects the gastric mucosa from experimental injury[1].[2].

   
   
   

teuvisside A

teuvisside A

C36H49NO17 (767.3)


   

alpha-Glc-(1->6)-beta-L-glycero-D-glucoheptose-alpha-GlcNAc-(1->2)-L-glicero-D-glucoheptose

alpha-Glc-(1->6)-beta-L-glycero-D-glucoheptose-alpha-GlcNAc-(1->2)-L-glicero-D-glucoheptose

C28H49NO23 (767.2695)


   
   

Pentagastrin

(3S)-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}-3-[(2S)-2-[(2S)-3-(1H-indol-3-yl)-2-(3-{[(2-methylpropoxy)carbonyl]amino}propanamido)propanamido]-4-(methylsulfanyl)butanamido]propanoic acid

C37H49N7O9S (767.3312)


V - Various > V04 - Diagnostic agents > V04C - Other diagnostic agents > V04CG - Tests for gastric secretion D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D005755 - Gastrins Pentagastrin (ICI-50123) is a potent, selective Cholecystokinin B (CCKB) receptor antagonists with IC50 values of 11 nM and 1100 nM for CCKB and CCKA, respectively. Pentagastrin enhances gastric mucosal defense mechanisms against acid and protects the gastric mucosa from experimental injury[1].[2].

   

2-hydroxy-4-[[(2S)-6-[hydroxy-[(E)-3-phenylprop-2-enoyl]amino]-1-methoxy-1-oxohexan-2-yl]amino]-2-[2-[[(2S)-6-[hydroxy-[(E)-3-phenylprop-2-enoyl]amino]-1-methoxy-1-oxohexan-2-yl]amino]-2-oxoethyl]-4-oxobutanoate

2-hydroxy-4-[[(2S)-6-[hydroxy-[(E)-3-phenylprop-2-enoyl]amino]-1-methoxy-1-oxohexan-2-yl]amino]-2-[2-[[(2S)-6-[hydroxy-[(E)-3-phenylprop-2-enoyl]amino]-1-methoxy-1-oxohexan-2-yl]amino]-2-oxoethyl]-4-oxobutanoate

C38H47N4O13- (767.3139)


   

methyl (7E,9Z,11R,13S,14R,15S,16R,17S,18S,19S,20E)-2-acetyloxy-14,16,18,19,31-pentahydroxy-3,7,11,13,17,19,21,27-octamethyl-6,12,28-trioxo-23,25-dioxa-5-azatetracyclo[20.7.1.14,29.026,30]hentriaconta-1,3,7,9,20,22(30),26,29(31)-octaene-15-carboxylate

methyl (7E,9Z,11R,13S,14R,15S,16R,17S,18S,19S,20E)-2-acetyloxy-14,16,18,19,31-pentahydroxy-3,7,11,13,17,19,21,27-octamethyl-6,12,28-trioxo-23,25-dioxa-5-azatetracyclo[20.7.1.14,29.026,30]hentriaconta-1,3,7,9,20,22(30),26,29(31)-octaene-15-carboxylate

C40H49NO14 (767.3153)


   

alpha-D-GlcpNAc-(1->2)-L-alpha-D-Hepp-(1->3)-[beta-D-Glcp-(1->4)]-L-alpha-D-Hepp

alpha-D-GlcpNAc-(1->2)-L-alpha-D-Hepp-(1->3)-[beta-D-Glcp-(1->4)]-L-alpha-D-Hepp

C28H49NO23 (767.2695)


   

4-[2-[(E,3E)-3-(2-tert-butyl-9-ethyl-6,8,8-trimethylpyrano[3,2-g]quinolin-4-ylidene)prop-1-enyl]-3-methyl-5-sulfo-1-(3-sulfopropyl)indol-1-ium-3-yl]butanoic acid

4-[2-[(E,3E)-3-(2-tert-butyl-9-ethyl-6,8,8-trimethylpyrano[3,2-g]quinolin-4-ylidene)prop-1-enyl]-3-methyl-5-sulfo-1-(3-sulfopropyl)indol-1-ium-3-yl]butanoic acid

C40H51N2O9S2+ (767.3036)


   

Hex3Cer 16:3;2O

Hex3Cer 16:3;2O

C34H57NO18 (767.3575)


   
   
   

N6-Methyl-dA phosphoramidite

N6-Methyl-dA phosphoramidite

C41H50N7O6P (767.356)


N6-Methyl-dA phosphoramidite can be used in the synthesis of oligodeoxyribonucleotides[1].

   

n-[2-(4-{[(2s,3r,4r,5s,6s)-5-hydroxy-6-methyl-3,4-bis({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})oxan-2-yl]oxy}phenyl)ethyl]-3-(4-methoxyphenyl)prop-2-enimidic acid

n-[2-(4-{[(2s,3r,4r,5s,6s)-5-hydroxy-6-methyl-3,4-bis({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})oxan-2-yl]oxy}phenyl)ethyl]-3-(4-methoxyphenyl)prop-2-enimidic acid

C36H49NO17 (767.3)


   

austrotaxine

NA

C41H53NO13 (767.3517)


{"Ingredient_id": "HBIN017387","Ingredient_name": "austrotaxine","Alias": "NA","Ingredient_formula": "C41H53NO13","Ingredient_Smile": "CC1=C2C(=O)C(C3(C(CC(C2(C)C)C(C1OC(=O)C)OC(=O)C)C(=C)C(CC3OC(=O)C)OC(=O)C(C(C4=CC=CC=C4)N(C)C)OC(=O)C)C)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2025","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

(2z)-n-[2-(4-{[(2s,3r,4r,5s,6s)-5-hydroxy-6-methyl-3,4-bis({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})oxan-2-yl]oxy}phenyl)ethyl]-3-(4-methoxyphenyl)prop-2-enimidic acid

(2z)-n-[2-(4-{[(2s,3r,4r,5s,6s)-5-hydroxy-6-methyl-3,4-bis({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})oxan-2-yl]oxy}phenyl)ethyl]-3-(4-methoxyphenyl)prop-2-enimidic acid

C36H49NO17 (767.3)


   

10-{[5-({5,14-dimethyl-6-oxo-2,4,9,13-tetraoxatricyclo[8.4.0.0³,⁸]tetradecan-12-yl}oxy)-4-(dimethylamino)-6-methyloxan-2-yl]oxy}-8-ethyl-1,7,8,11-tetrahydroxy-9,10-dihydro-7h-tetracene-5,12-dione

10-{[5-({5,14-dimethyl-6-oxo-2,4,9,13-tetraoxatricyclo[8.4.0.0³,⁸]tetradecan-12-yl}oxy)-4-(dimethylamino)-6-methyloxan-2-yl]oxy}-8-ethyl-1,7,8,11-tetrahydroxy-9,10-dihydro-7h-tetracene-5,12-dione

C40H49NO14 (767.3153)


   

(8r)-10-{[(4s)-5-{[(10s)-5,14-dimethyl-6-oxo-2,4,9,13-tetraoxatricyclo[8.4.0.0³,⁸]tetradecan-12-yl]oxy}-4-(dimethylamino)-6-methyloxan-2-yl]oxy}-8-ethyl-1,7,8,11-tetrahydroxy-9,10-dihydro-7h-tetracene-5,12-dione

(8r)-10-{[(4s)-5-{[(10s)-5,14-dimethyl-6-oxo-2,4,9,13-tetraoxatricyclo[8.4.0.0³,⁸]tetradecan-12-yl]oxy}-4-(dimethylamino)-6-methyloxan-2-yl]oxy}-8-ethyl-1,7,8,11-tetrahydroxy-9,10-dihydro-7h-tetracene-5,12-dione

C40H49NO14 (767.3153)


   

(2e)-n-[2-(4-{[(2s,3r,4r,5s,6s)-5-hydroxy-6-methyl-3,4-bis({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})oxan-2-yl]oxy}phenyl)ethyl]-3-(4-methoxyphenyl)prop-2-enimidic acid

(2e)-n-[2-(4-{[(2s,3r,4r,5s,6s)-5-hydroxy-6-methyl-3,4-bis({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})oxan-2-yl]oxy}phenyl)ethyl]-3-(4-methoxyphenyl)prop-2-enimidic acid

C36H49NO17 (767.3)